Navigation Links
Bioniche Pharma Acquires Duraclon(R) (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP
Date:11/12/2009

LAKE FOREST, Ill., Nov. 12 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the acquisition of Duraclon® (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP from Xanodyne Pharmaceuticals, Inc.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

"Bioniche Pharma is very pleased to expand our product line with these injectable drugs," said Steve Thornton, Bioniche Pharma CEO. "These two products represent our commitment to expanding our product line with a combination of brand and generic drugs, which strengthens our position as a specialty injectables pharmaceutical company."

Duraclon®(clonidine hydrochloride injection) has a black box warning relating to risk of hemodynamic instability, especially hypotension and bradycardia in obstetrical, postpartum and peri-operative pain management. Methadone Hydrochloride Injection USP has black box warnings relating to peri-operative pain management and to conditions for distribution and use for the treatment of opioid addiction. Please refer to the Bioniche Pharma website for the complete prescribing information, including the boxed warnings, for these products.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology, and dermatology. An internal development pipeline and an aggressive acquisition strategy for products fuel the company's growth. RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois, acquired Bioniche Pharma in February 2006. More information about Bioniche Pharma can be found at www.bionichepharma.com .

Duraclon® is a registered trademark of Astellas US LLC

SOURCE Bioniche Pharma


'/>"/>
SOURCE Bioniche Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Pharma and Synerx Pharma Launch Fomepizole Injection
2. Bioniche Reports Fiscal 2009 Year-End Results
3. Bioniche Phase III Clinical Trial with Urocidin(TM) Given Continued Green Light by DMC
4. Bioniche Repays Revolving Credit Facility
5. Bioniche Provides a Corporate Update
6. Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
7. Bioniche Represented at House of Commons Sub-Committee on Food Safety
8. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
9. Bioniche Reports Fiscal 2009 Third Quarter
10. Bioniche Provides a Corporate Update
11. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... ... NJ, is a diverse community of over 1,000 passionate employees, caregivers, volunteers, thought ... After Parker at Stonegate changed ownership, it was time to refresh the carpeting ...
(Date:8/18/2017)... (PRWEB) , ... August 19, 2017 , ... ... Tourism Authority of Thailand presided over the Amazing Thailand Health and Wellness Tourism ... Thailand. , Mr. Noppadon Pakprot, Deputy Governor for Tourism Products and Business at ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions for ... agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation Systems, ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... & Hearing” campaign, advocating for active, healthy lifestyles and highlighting the importance of ... individuals with hearing impairments and shares the latest innovations in hearing aid technology. ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... financial consultations to communities throughout the greater DC region, is inaugurating a “New ... of rescuing local animals and training them to be companions for veterans in ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/14/2017)... TIKVAH, Israel , Aug. 15, 2017 ... developer of adult stem cell technologies for neurodegenerative diseases, ... 30, 2017. "We ... pivotal Phase 3 trial to investigate NurOwn ® ... Chief Executive Officer of BrainStorm. "We have agreements with ...
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
Breaking Medicine Technology: